Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 18];8(6):s422. Available from: https://skin.dermsquared.com/skin/article/view/3089